Streetbeat News

Partnerships

FWBI

First Wave BioPharma has entered into a license agreement for capeserod with Sanofi, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:50 am

SPIR

Spire Global, Inc. (NYSE:SPIR) has been selected by data firm Estuaire to supply global aviation insights. Spire will provide detailed aircraft positional data and its Flight Report for post-flight analytics and reporting needs. The terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:49 am

ETN

Eaton has entered into an exclusive global alliance with Traxen to sell, distribute, service, and provide installation support for the iQ-Cruise system. The collaboration aims to improve fuel efficiency and environmental sustainability in the commercial transportation industry, potentially boosting fleet profitability.

Portfolio Pulse from Charles Gross

September 14, 2023 | 10:45 am

GOOGL

VIAV

VIAVI Solutions has partnered with Google Cloud to provide cloud-based network intelligence and optimization. This partnership will allow VIAVI to leverage Google Cloud's capabilities to enhance its network performance solutions.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:36 am

FWBI

SNY

First Wave Biopharma has entered into a license agreement with Sanofi. Sanofi could potentially receive up to $46M in development and regulatory milestone payments, and up to $235M in potential commercial milestone payments.

Portfolio Pulse from Charles Gross

September 14, 2023 | 10:24 am

BNOX

MRK

Bionomics announced that data for MK-4334, a drug developed in collaboration with Merck, was presented at the Society for Chemical Industry and Royal Society of Chemistry Medicinal Chemistry Symposium.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:04 am

FWBI

SNY

First Wave BioPharma Inc (FWBI) has entered into a licensing agreement with Sanofi SA (SNY) for Capeserod, a drug that First Wave plans to repurpose for gastrointestinal indications. This follows disappointing results from First Wave's Phase 2 SPAN trial. The agreement includes a modest upfront payment, backend milestone payments, and single-digit royalties on net sales. First Wave will request a meeting with the FDA to establish a development and regulatory pathway for Capeserod.

Portfolio Pulse from Vandana Singh

September 14, 2023 | 10:00 am

FWBI

SNY

First Wave BioPharma has entered into an exclusive global license agreement with Sanofi for Capeserod, a drug for gastrointestinal indications. The terms of the deal have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:00 am

VLVCY

VLVLY

Volvo Group has announced a partnership with H2 Green Steel to develop near zero emission steel. This collaboration aims to significantly reduce the carbon footprint of Volvo's products.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 6:54 am

AZN

AstraZeneca has partnered with Future Biogas to create the UK's first unsubsidized biomethane supply. The pharmaceutical company has committed £100M to sustainability efforts.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 6:41 am